Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

HungaryBack to Hungary

Clinical trials in Debrecen – page 4

560 clinical trials in Debrecen, Hungary across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Debrecen at a glance
560
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

560 trials in Debrecen

Open in trial search

Obstructive sleep apnoea syndrome

Recruiting

A Phase 3 Randomized, Double-blind,Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants with Obstructive Sleep Apnea not on Positive Airway Pressure Therapy and Living with Overweight or Obesity (MARITIME-OSA-2)

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Obesity

Recruiting

Long‑term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity and Type 2 Diabetes

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Heart failure with reduced ejection fraction

Recruiting

A study of the safety and efficacy of AC01 in patients with heart failure with reduced ejection fraction

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Sponsor:AnaCardio AB

Autoimmune hepatitis

Recruiting

A Phase 2/3 Randomized Double‑Blind Study of Inebilizumab for Safety and Tolerability in Patients with Autoimmune Hepatitis

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Chronic graft versus host disease

Recruiting

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Hereditary haemorrhagic telangiectasia

Recruiting

A Phase 3 Study of Engasertib to Evaluate Safety and Effectiveness in Adults with Moderate to Severe Hereditary Hemorrhagic Telangiectasia

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Sponsor:Vaderis Therapeutics AG

Dermatitis atopic

Recruiting

Study of Camoteskimab and Sodium Chloride Placebo in Adults with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride

Plasma cell myeloma refractory

Recruiting

Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma Patients Receiving JNJ-79635322 and Human Normal Immunoglobulin (IV)

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Janssen Cilag International

Gastrointestinal stromal tumour

Recruiting

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate
  • Sponsor:Glaxosmithkline Research & Development Limited

Polycythaemia vera

Recruiting

A Phase 3 Study of Sapablursen Compared with Placebo in Adults with Polycythemia Vera

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Sapablursen
  • Sponsor:Deciphera Pharmaceuticals Inc.

Neovascular age-related macular degeneration

Recruiting

Efficacy and safety of ABP 938 compared with aflibercept in participants with neovascular age‑related macular degeneration

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Amgen Inc.

Immune thrombocytopenia

Recruiting

Phase 3 Study of Romiplostim Combined with Prednisolone versus Prednisolone Alone in Adults with Previously Untreated Primary Immune Thrombocytopenia (ITP)

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Amgen Inc.

Other cities in Hungary

The busiest research cities in the country

All 71 cities in Hungary

Clinical research in Debrecen

What the registry says about research in the country

01 Dermatology Research

Comprehensive studies evaluating novel treatments for plaque psoriasis and chronic urticaria. Multiple trials are investigating innovative therapies for both moderate to severe cases, including genital manifestations.

  • Plaque Psoriasis Treatment
  • Chronic Spontaneous Urticaria Management
  • Genital Psoriasis Therapy

Focus on long-term safety and efficacy of new therapeutic agents for chronic skin conditions.

02 Cardiovascular Studies

Leading research into heart failure prevention and cardiovascular disease management. Trials examining innovative treatments and preventive approaches for high-risk patients.

  • Heart Failure Prevention
  • Cardiovascular Disease Treatment
  • Lipoprotein Management

Emphasis on reducing major cardiovascular events and improving patient outcomes.

03 Metabolic Disorders

Groundbreaking research addressing obesity and type 2 diabetes. Studies evaluating combination therapies and novel approaches for weight management in diverse patient populations.

  • Weight Management Solutions
  • Diabetes Treatment
  • Metabolic Health Optimization

Investigation of treatments combining weight reduction with diabetes management.

Back to HungaryAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.